Jci_page_head_homepage_01 Jci_page_head_homepage_02
Michael J. Farrell, Jarrett L. Burch, Kathleen Wallis, Linda Rowley, Donna Kumiski, Harriet Stadt, Robert E. Godt, Tony L. Creazzo, Margaret L. Kirby
Published in Volume 107, Issue 12
J Clin Invest. 2001; 107(12):1509–1517 doi:10.1172/JCI9317
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

Stage 16 ventral pharynx or anti–FGF-2-neutralizing Ab alone had no effect on development of myocardial calcium transients. Each bar shows the average peak diastolic and peak systolic calcium. (a) The effect of stage 16 ventral pharynx (VP) on myocardial calcium transients. (b) The effect of anti–FGF-2-neutralizing Ab alone on myocardial calcium transients.